
Loading, please wait...

Loading, please wait...

The Clear Cell Likelihood Score (ccLS) has emerged as a critical tool for the non-invasive characterization of small renal masses (SRMs). This standardized scoring system utilizes multiparametric MRI features to predict the histopathology of renal lesions. Consequently, it helps clinicians differentiate between clear cell renal cell carcinoma (ccRCC) and other subtypes. A recent institutional study evaluated how the score performs in patients who are specifically undergoing percutaneous biopsy for indeterminate masses.
Researchers retrospectively analyzed 60 consecutive patients who received both MRI and percutaneous renal mass biopsies between 2013 and 2023. Three radiologists independently assigned Clear Cell Likelihood Score values while remaining blinded to the final pathology. The cohort included a variety of histopathological results: 47% were ccRCC, 25% were papillary RCC (pRCC), and 18% were oncocytomas. In addition, chromophobe RCC and fat-poor angiomyolipomas were identified in a small percentage of cases.
The results demonstrated robust performance across all readers. Specifically, the Area Under the Curve (AUC) for diagnosing ccRCC ranged from 0.75 to 0.88. Furthermore, the accuracy for identifying pRCC was even higher, with AUC values reaching 0.92 for the primary reader. Statistical analysis showed that interreader agreement was substantial when using thresholds of ccLS ≥ 3 and ccLS ≥ 4. These findings suggest that the scoring system is reproducible and reliable in a clinical setting.
Implementing the ccLS can significantly refine the management of small renal masses. By providing a standardized probability of malignancy, it assists urologists and oncologists in deciding between active surveillance, biopsy, or surgical intervention. Moreover, the high accuracy in distinguishing ccRCC from more indolent subtypes may reduce unnecessary invasive procedures for some patients.
The ccLS is a five-point Likert scale designed to standardize the reporting of multiparametric MRI findings for solid renal masses. It specifically estimates the likelihood that a mass represents clear cell renal cell carcinoma, which is the most common and often aggressive subtype.
By providing a standardized assessment, the ccLS reduces variability in imaging interpretation. This allows for better risk stratification, helping clinicians identify which patients may benefit from a biopsy and which might safely undergo active surveillance.
The study reported a high diagnostic accuracy with an AUC of up to 0.88 for ccRCC. Additionally, it showed substantial interobserver agreement, indicating that different radiologists can consistently reach similar conclusions using this scoring system.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.
References
Brembilla G et al. Diagnostic performance of the clear cell likelihood score (ccLS) for small renal masses characterization in patients undergoing percutaneous biopsy. Radiol Med. 2026 Feb 21. doi: 10.1007/s11547-025-02169-7. PMID: 41722020.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


New research confirms that the Clear Cell Likelihood Score (ccLS) on MRI offers high diagnostic accuracy for characterizing indeterminate small renal masses...
6 months ago

A nationwide study reveals stable pathogen specification rates in infectious diarrhea hospitalizations from 2016 to 2023, accompanied by a marked decline in Clostridioides difficile cases, emphasizing the need for targeted diagnostic stewardship and thoughtful multiplex testing in hospital medicine.
4 days back

A real-world cohort study evaluates anti-Müllerian hormone recovery and fertility outcomes in high-risk GTN patients treated with EMA/CO versus FAEV chemotherapy, demonstrating robust ovarian reserve recovery by six months post-treatment.
4 days back

A real-world Japanese claims database analysis reveals that the 2021 heart failure guideline update drove significant improvements in guideline-directed medical therapy (GDMT). The study highlighted substantial increases in the prescription of sacubitril/valsartan and dapagliflozin among heart failure patients.
4 days back

A multicenter prospective cohort study reveals that 54.1% of patients achieve clinically meaningful neuropathic pain relief after surgery for degenerative cervical myelopathy, driving substantial gains in motor function, mental health, and quality of life.
4 days back

The ferroptosis-immunity axis represents a critical driver of diabetic kidney disease progression. This review explores iron-dependent lipid peroxidation, innate immune cross-talk, emerging candidate biomarkers, and promising targeted therapies to delay renal decline alongside standard glycemic control.
4 days back